Treatment for locally advanced pancreatic cancer using a new technology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness and safety of irreversible electroporation (IRE), a novel non-thermal ablation technique, in patients with locally advanced pancreatic cancer who are not candidates for surgery. The trial aims to provide a prospective validation of IRE in combination with chemotherapy, as current treatment options are limited and often ineffective. By minimizing damage to surrounding tissues, IRE may offer improved disease control and overall survival compared to traditional therapies. The study will enroll adult patients with biopsy-proven locally advanced pancreatic adenocarcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists.

Exclusion Criteria:

1. Pregnancy
2. Metastatic pancreatic cancer
3. Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.

Where it's running

• Allan Blair Cancer Center
  Regina, Saskatchewan, Canada Recruiting
• Saskatoon Cancer Center
  Saskatoon, Saskatchewan, Canada Recruiting

Study contacts

• Principal investigator: Shahid Ahmed, MD, PhD — University of Saskatchewan
• Study coordinator: Shahid Ahmed, MD, PhD
• Email: shahid.ahmed@saskcancer.ca
• Phone: 3066122617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemotherapy followed by ablative SBRT for locally advanced inoperable pancreatic cancer

  This trial will try chemotherapy followed by high-dose focused radiation (SBRT) as the first treatment for adults with locally advanced, inoperable pancreatic cancer.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07407231

• Chemotherapy With IMD10 (Focused Ultrasound) for Borderline Resectable or Locally Advanced Pancreatic Cancer

  This trial tests whether adding IMD10 focused ultrasound to a standard chemotherapy regimen helps people with borderline resectable or locally advanced pancreatic cancer see better survival.

  Recruiting IMGT Co., Ltd. · Boston, Massachusetts and 4 other locations · NCT07325214

• Personalized management for borderline resectable and locally advanced pancreatic cancer

  This study is testing if giving chemotherapy first can help people with borderline resectable and locally advanced pancreatic cancer have surgery and improve their chances of survival.

  Recruiting Oslo University Hospital · Bergen, Norway and 4 other locations · NCT06944587

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination treatment for advanced pancreatic cancer to see if it helps patients who haven't had treatment before.

  Recruiting Phase 1/2 Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06761027

• Alpha DaRT for Locally Advanced Pancreatic Cancer test

  This trial tests inserting Alpha DaRT sources into a locally advanced pancreatic tumor to see if it can become resectable.

  Recruiting Alpha Tau Medical LTD. · Bordeaux and 11 other locations · NCT06755359

• Comparing two treatments for locally advanced pancreatic cancer

  This study is testing two different treatment combinations for people with locally advanced pancreatic cancer to see which one works better.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu and 1 other locations · NCT06494514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.